These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30478722)

  • 21. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
    Ohyashiki K; Kodama A; Ohyashiki JH
    Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.
    Dahabreh IJ; Zoi K; Giannouli S; Zoi C; Loukopoulos D; Voulgarelis M
    Leuk Res; 2009 Jan; 33(1):67-73. PubMed ID: 18632151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia.
    Antonioli E; Guglielmelli P; Poli G; Bogani C; Pancrazzi A; Longo G; Ponziani V; Tozzi L; Pieri L; Santini V; Bosi A; Vannucchi AM;
    Haematologica; 2008 Jan; 93(1):41-8. PubMed ID: 18166784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia.
    Gadomska G; Stankowska K; Boinska J; Bartoszewska-Kubiak A; Haus O; Rość D
    Blood Coagul Fibrinolysis; 2016 Oct; 27(7):817-821. PubMed ID: 26945263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders.
    Musolino C; Allegra A; Penna G; Centorrino R; Cuzzola M; D'Angelo A; Iacopino P; Alonci A
    Acta Haematol; 2009; 122(1):46-9. PubMed ID: 19816006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia.
    Ohyashiki K; Kiguchi T; Ito Y; Fujimoto H; Gotoh A; Tauchi T; Miyazawa K; Kimura Y; Ohyashiki JH
    Int J Hematol; 2008 May; 87(4):446-448. PubMed ID: 18409076
    [No Abstract]   [Full Text] [Related]  

  • 28. MPL W515L mutation in pediatric essential thrombocythemia.
    Farruggia P; D'Angelo P; La Rosa M; Scibetta N; Santangelo G; Lo Bello A; Duner E; Randi ML; Putti MC; Santoro A
    Pediatr Blood Cancer; 2013 Aug; 60(8):E52-4. PubMed ID: 23441089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired JAK-2 V617F Mutational Analysis in Pakistani Patients with Essential Thrombocythemia.
    Sultan S; Irfan SM
    Asian Pac J Cancer Prev; 2015; 16(16):7327-30. PubMed ID: 26514532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain.
    Ziakas PD
    Haematologica; 2008 Sep; 93(9):1412-4. PubMed ID: 18641024
    [No Abstract]   [Full Text] [Related]  

  • 31. Cerebral Venous Sinus Thrombosis as the First Manifestation of JAK2
    Chen WB; Wang XL
    Chin Med J (Engl); 2018 Mar; 131(6):748-750. PubMed ID: 29521303
    [No Abstract]   [Full Text] [Related]  

  • 32. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.
    Finazzi G; Rambaldi A; Guerini V; Carobbo A; Barbui T
    Haematologica; 2007 Jan; 92(1):135-6. PubMed ID: 17229651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic factors affecting thrombosis in patients with essential thrombocythemia by heparin treatment.
    Kawada T
    J Thromb Thrombolysis; 2019 Oct; 48(3):514-515. PubMed ID: 31127465
    [No Abstract]   [Full Text] [Related]  

  • 34. Extrinsic blood coagulation pathway and risk factors for thrombotic events in patients with essential thrombocythemia.
    Stankowska K; Gadomska G; Boinska J; Michalska M; Bartoszewska-Kubiak A; Rość D
    Pol Arch Med Wewn; 2016 May; 126(5):340-6. PubMed ID: 27243342
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.
    Trifa AP; Cucuianu A; Popp RA; Coadă CA; Costache RM; Militaru MS; Vesa ŞC; Pop IV
    Ann Hematol; 2014 Feb; 93(2):203-9. PubMed ID: 23828072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translocation t(1;9) is a recurrent cytogenetic abnormality associated with progression of essential thrombocythemia patients displaying the JAK2 V617F mutation.
    Leon A; Staropoli JF; Hernandez JM; Longtine JA; Kuo FC; Dal Cin P
    Leuk Res; 2011 Sep; 35(9):1188-92. PubMed ID: 21376394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the prevalence and prospective clinical impact of the JAK2 V617F mutation in coronary patients.
    Muendlein A; Gasser K; Kinz E; Stark N; Leiherer A; Rein P; Saely CH; Grallert H; Peters A; Drexel H; Lang AH
    Am J Hematol; 2014 Mar; 89(3):295-301. PubMed ID: 24265174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.
    Michiels JJ; Commandeur S; Hoogenboom GJ; Wegman JJ; Scholten L; van Rijssel RH; De Raeve H
    Ann Hematol; 2007 Nov; 86(11):793-800. PubMed ID: 17687555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis.
    Lim KH; Chang YC; Gon-Shen Chen C; Lin HC; Wang WT; Chiang YH; Cheng HI; Su NW; Lin J; Chang YF; Chang MC; Hsieh RK; Kuo YY; Chou WC
    Blood Cancer J; 2015 Mar; 5(3):e295. PubMed ID: 25794131
    [No Abstract]   [Full Text] [Related]  

  • 40. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.